Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: ("saves" OR "caves")
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"Canadian Agency for Drugs and Technologies in Health"
Search alternatives
:
"saves" »
"waves"
,
"saved"
,
"paves"
"caves" »
"waves"
Showing
1
-
17
of
17
Search:
'("saves" OR "caves")'
,
query time: 0.07s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Switching from innovator to biosimilar (subsequent entry) infliximab : an updated review of the clinical effectiveness, cost-effectiveness, and guidelines
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
...The potential cost
savings
of switching to biosimilars without compromising on clinical...
”
Read Now
2
Switching from innovator to biosimilar (subsequent entry) infliximab : an updated review of the clinical effectiveness, cost-effectiveness, and guidelines
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
...The potential cost
savings
of switching to biosimilars without compromising on clinical...
”
Read Now
3
Switching from innovator to biosimilar (subsequent entry) Infliximab : a review of the clinical effectiveness, cost-effectiveness, and guidelines
Published 2015
CADTH Rapid Response Service
“
...The availability of biosimilar infliximab (INX) has been postulated to offer cost
savings
compared...
”
Read Now
4
Switching from innovator to biosimilar (subsequent entry) Infliximab : a review of the clinical effectiveness, cost-effectiveness, and guidelines
Published 2015
CADTH Rapid Response Service
“
...The availability of biosimilar infliximab (INX) has been postulated to offer cost
savings
compared...
”
Read Now
5
Junctional tourniquets for controlling hemorrhage from wounds in adults : a review of clinical effectiveness, cost-effectiveness, safety, and guidelines
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
.... The introduction and appropriate use of junctional tourniquets has the potential to
save
many lives. A review...
”
Read Now
6
Junctional tourniquets for controlling hemorrhage from wounds in adults : a review of clinical effectiveness, cost-effectiveness, safety, and guidelines
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
.... The introduction and appropriate use of junctional tourniquets has the potential to
save
many lives. A review...
”
Read Now
7
Dialysis modalities for the treatment of end-stage kidney disease : recommendations
Published 2017
CADTH
“
... effectiveness and potential cost
savings
that home dialysis therapies may yield, it is often argued...
”
Read Now
8
Pharmacoeconomic report: Apomorphine hydrochloride (Kynmobi) (Sunovion Pharmaceuticals Canada Inc.) : indication: the acute, intermittent treatment of "OFF" episodes in patients wi...
Published 2021
Canadian Agency for Drugs and Technologies in Health
“
... of apomorphine hydrochloride subcutaneous (APO SC), representing
savings
of $3,695 per patient over 5 years. Some...
”
Read Now
9
Pharmacoeconomic report: Indacaterol acetate-glycopyrronium bromide-mometasone furoate (Enerzair Breezhaler) : (Novartis Pharmaceuticals Canada Inc.) : indication: asthma maintenan...
Published 2021
Canadian Agency for Drugs and Technologies in Health
“
...) + tiotropium (TIO; cost
savings
= $6,674, incremental quality-adjusted life-years [QALYs] = 0.0085). CADTH...
”
Read Now
10
Dialysis modalities for the treatment of end-stage kidney disease : a health technology assessment : project protocol
Published 2016
Canadian Agency for Drugs and Technologies in Health
Read Now
11
Dialysis modalities for the treatment of end-stage kidney disease : a health technology assessment : project protocol
Published 2016
Canadian Agency for Drugs and Technologies in Health
Read Now
12
Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication: for the treatment of adult patients with active ankylosing spondylitis who have responded i...
Published 2020
CADTH
Read Now
13
Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication: for the treatment of adult patients with active ankylosing spondylitis who have responded i...
Published 2020
CADTH
Read Now
14
Pharmacoeconomic review report: Glucagon nasal powder (Baqsimi) (Eli Lilly Canada Inc.) : indication: for the treatment of severe hypoglycemic reactions which may occur in the mana...
Published 2020
CADTH
Read Now
15
Pharmacoeconomic review report: Glucagon nasal powder (Baqsimi) (Eli Lilly Canada Inc.) : indication: for the treatment of severe hypoglycemic reactions which may occur in the mana...
Published 2020
CADTH
Read Now
16
Pharmacoeconomic review report: Iron isomaltoside 1000 (Monoferric) (Pharmacosmos A/S) : indication: for the treatment of iron deficiency anemia in adult patients who have intolera...
Published 2020
CADTH
Read Now
17
Pharmacoeconomic review report: Iron isomaltoside 1000 (Monoferric) (Pharmacosmos A/S) : indication: for the treatment of iron deficiency anemia in adult patients who have intolera...
Published 2020
CADTH
Back
Narrow Search
Remove Filters
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Year of Publication
From:
To:
Classification
330 - Economics
11
610 - Medicine & health
9
140 - Specific philosophical schools
2
Language
English
17
Collection
National Center for Biotechnology Information
17
Author
Canadian Agency for Drugs and Technologies in Health
Canadian Agency for Drugs and Technologies in Health Rapid Response Service
2
Recently Uploaded
Last Month
1
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&lookfor=%28%22saves%22+OR+%22caves%22%29&type=AllFields
Send by Email
×
Loading...